Nautilus Biotechnology, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
NAUT$2.32-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Nautilus Biotechnology, Inc.Consolidated Statements of Cash FlowsYears Ended December 31, 2025 and 2024
| (in thousands) | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(59,001) | $(70,780) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation | 6,844 | 12,701 |
| Amortization of operating lease right-of-use assets | 4,712 | 4,378 |
| Depreciation | 1,753 | 2,059 |
| In-process research and development | — | 760 |
| Amortization (accretion) of premiums (discounts) on securities, net | (1,420) | (2,804) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 544 | 666 |
| Accounts payable | (69) | (578) |
| Accrued expenses and other liabilities | 629 | (1,397) |
| Operating lease liabilities | (4,688) | (4,150) |
| Net cash used in operating activities | (50,696) | (59,145) |
| Cash flows from investing activities | ||
| Proceeds from maturities of securities | 108,991 | 155,410 |
| Purchases of securities | (72,490) | (86,278) |
| Purchases of property and equipment | (1,277) | (2,122) |
| Cash paid in connection with asset acquisition | — | (760) |
| Net cash provided by investing activities | 35,224 | 66,250 |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options | 58 | 620 |
| Proceeds from issuance of common stock under employee stock purchase plan | 156 | 524 |
| Net cash provided by financing activities | 214 | 1,144 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (15,258) | 8,249 |
| Cash, cash equivalents and restricted cash at beginning of period | 28,648 | 20,399 |
| Cash, cash equivalents and restricted cash at end of period | $13,390 | $28,648 |
| Supplementary cash flow information on non-cash activities: | ||
| Acquisitions of property and equipment included in accounts payable | $99 | $74 |
| Remeasurement of lease liabilities and right-of-use assets | $4,228 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.